Connecting you to content on EBSCOhost

Works by Lindemann, Justin P.

Results: 4

1

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.

Published in:

NPJ Breast Cancer, 2021, v. 7, n. 1, p. 1, doi. 10.1038/s41523-021-00251-7

By:

Smyth, Lillian M.;
Batist, Gerald;
Meric-Bernstam, Funda;
Kabos, Peter;
Spanggaard, Iben;
Lluch, Ana;
Jhaveri, Komal;
Varga, Andrea;
Wong, Andrea;
Schram, Alison M.;
Ambrose, Helen;
Carr, T. Hedley;
de Bruin, Elza C.;
Salinas-Souza, Carolina;
Foxley, Andrew;
Hauser, Joana;
Lindemann, Justin P. O.;
Maudsley, Rhiannon;
McEwen, Robert;
Moschetta, Michele

Publication type:

Article

2

Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363.

Published in:

2017

By:

Weller, Michael;
Roth, Patrick;
Sahm, Felix;
Burghardt, Isabel;
Schuknecht, Bernhard;
Rushing, Elisabeth J.;
Regli, Luca;
Lindemann, Justin P.;
von Deimling, Andreas

Publication type:

journal article

3

Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients.

Published in:

PLoS ONE, 2017, v. 12, n. 5, p. 1, doi. 10.1371/journal.pone.0175779

By:

de Bruin, Elza C.;
Whiteley, Jessica L.;
Corcoran, Claire;
Kirk, Pauline M.;
Fox, Jayne C.;
Armisen, Javier;
Lindemann, Justin P. O.;
Schiavon, Gaia;
Ambrose, Helen J.;
Kohlmann, Alexander

Publication type:

Article

4

Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study.

Published in:

Breast Cancer Research & Treatment, 2012, v. 136, n. 2, p. 503, doi. 10.1007/s10549-012-2192-4

By:

Robertson, John F. R.;
Lindemann, Justin P. O.;
Llombart-Cussac, Antonio;
Rolski, Janusz;
Feltl, David;
Dewar, John;
Emerson, Laura;
Dean, Andrew;
Ellis, Matthew J.

Publication type:

Article